Axsome Therapeutics, Inc. (0HKF.L)
USD 94.11
(0.14%)
USD 94.11
(0.14%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -231.82 Million USD | -3.63% |
| 2022 | -176.5 Million USD | -41.53% |
| 2021 | -124.7 Million USD | -25.79% |
| 2020 | -99.14 Million USD | -47.43% |
| 2019 | -67.24 Million USD | -104.72% |
| 2018 | -32.84 Million USD | -20.92% |
| 2017 | -27.16 Million USD | 1.38% |
| 2016 | -27.54 Million USD | -199.51% |
| 2015 | -9.19 Million USD | -62.13% |
| 2014 | -5.67 Million USD | -208.36% |
| 2013 | -1.83 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -68.68 Million USD | 29.99% |
| 2024 Q2 | -75.88 Million USD | -13.63% |
| 2023 Q2 | -65.05 Million USD | -895.36% |
| 2023 Q4 | -98.11 Million USD | -57.94% |
| 2023 Q3 | -62.12 Million USD | 4.51% |
| 2023 Q1 | -6.53 Million USD | 88.27% |
| 2023 FY | -182.9 Million USD | -3.63% |
| 2022 Q4 | -55.71 Million USD | -31.24% |
| 2022 Q2 | -40.04 Million USD | -4.58% |
| 2022 Q1 | -38.28 Million USD | -17.42% |
| 2022 FY | -176.5 Million USD | -41.53% |
| 2022 Q3 | -42.45 Million USD | -6.03% |
| 2021 Q3 | -33.4 Million USD | -8.3% |
| 2021 Q4 | -32.6 Million USD | 2.39% |
| 2021 Q1 | -27.84 Million USD | -0.36% |
| 2021 Q2 | -30.84 Million USD | -10.79% |
| 2021 FY | -124.7 Million USD | -25.79% |
| 2020 FY | -99.14 Million USD | -47.43% |
| 2020 Q3 | -21.12 Million USD | -18.83% |
| 2020 Q2 | -17.77 Million USD | 45.28% |
| 2020 Q1 | -32.49 Million USD | -33.01% |
| 2020 Q4 | -27.74 Million USD | -31.32% |
| 2019 Q1 | -10.42 Million USD | -10.28% |
| 2019 Q4 | -24.42 Million USD | -28.93% |
| 2019 Q3 | -18.94 Million USD | -40.89% |
| 2019 FY | -67.24 Million USD | -104.72% |
| 2019 Q2 | -13.44 Million USD | -29.04% |
| 2018 FY | -32.84 Million USD | -20.92% |
| 2018 Q4 | -9.45 Million USD | -14.64% |
| 2018 Q3 | -8.24 Million USD | -3.18% |
| 2018 Q2 | -7.98 Million USD | -11.54% |
| 2018 Q1 | -7.16 Million USD | -11.16% |
| 2017 FY | -27.16 Million USD | 1.38% |
| 2017 Q1 | -7.67 Million USD | -0.61% |
| 2017 Q3 | -6.29 Million USD | 6.72% |
| 2017 Q2 | -6.75 Million USD | 12.01% |
| 2017 Q4 | -6.44 Million USD | -2.33% |
| 2016 FY | -27.54 Million USD | -199.51% |
| 2016 Q4 | -7.62 Million USD | -5.8% |
| 2016 Q3 | -7.2 Million USD | -5.57% |
| 2016 Q2 | -6.82 Million USD | -16.05% |
| 2016 Q1 | -5.88 Million USD | -86.49% |
| 2015 FY | -9.19 Million USD | -62.13% |
| 2015 Q4 | -3.15 Million USD | -55.87% |
| 2015 Q3 | -2.02 Million USD | 2.93% |
| 2015 Q2 | -2.08 Million USD | -7.85% |
| 2015 Q1 | -1.93 Million USD | 0.78% |
| 2014 FY | -5.67 Million USD | -208.36% |
| 2014 Q1 | -921.39 Thousand USD | 0.0% |
| 2014 Q4 | -1.94 Million USD | -14.83% |
| 2014 Q3 | -1.69 Million USD | -84.15% |
| 2014 Q2 | -921.39 Thousand USD | 0.0% |
| 2013 FY | -1.83 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -37.028% |
| Dynavax Technologies Corporation | -37.02 Million USD | -526.08% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -4299.791% |
| Perrigo Company plc | 151.9 Million USD | 252.617% |
| Illumina, Inc. | -1.06 Billion USD | 78.314% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 103.38% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 49.664% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 98.353% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 111.726% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -109.578% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 105.728% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -419.007% |
| Waters Corporation | 817.67 Million USD | 128.352% |
| Biogen Inc. | 1.29 Billion USD | 117.877% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 15.394% |
| Evolus, Inc. | -49.23 Million USD | -370.873% |
| Adicet Bio, Inc. | -152.03 Million USD | -52.478% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -90.81% |
| bluebird bio, Inc. | -244.26 Million USD | 5.092% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -49.023% |
| FibroGen, Inc. | -281.81 Million USD | 17.739% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 117.172% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -414.283% |
| Homology Medicines, Inc. | -48.25 Million USD | -380.417% |
| Geron Corporation | -193.94 Million USD | -19.532% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 17.844% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -215.434% |
| Myriad Genetics, Inc. | -123.7 Million USD | -87.409% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -129.924% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 55.011% |
| Zoetis Inc. | 3.06 Billion USD | 107.554% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -380.965% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 121.321% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 219.226% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 105.382% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -492.1% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 34.463% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 16.007% |
| Verastem, Inc. | -92.08 Million USD | -151.754% |
| Nektar Therapeutics | -137.42 Million USD | -68.692% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -138.118% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 13.441% |
| OPKO Health, Inc. | -157.02 Million USD | -47.639% |
| Exelixis, Inc. | 170.88 Million USD | 235.661% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 192.397% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 316.089% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -315.785% |
| uniQure N.V. | -282.87 Million USD | 18.046% |
| Imunon, Inc. | -21.03 Million USD | -1002.331% |
| Blueprint Medicines Corporation | -486.27 Million USD | 52.327% |
| Insmed Incorporated | -709.62 Million USD | 67.331% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 168.674% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 40.783% |
| TG Therapeutics, Inc. | 20.63 Million USD | 1223.564% |
| Incyte Corporation | 620.52 Million USD | 137.359% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 68.086% |